Drug intelligence / Profile preview

MIC2634

Development stage: Preclinical
Lead developer: Micar Innovation
Modality: Small Molecules

Overview

MIC2634 is a small molecule therapeutic candidate currently in preclinical development by Micar Innovation. It is being investigated for the treatment of iminoglycinuria, a rare genetic disorder characterized by the impaired renal and intestinal transport of glycine and imino acids (proline and hydroxyproline). As of the latest pipeline updates, the specific molecular target and mechanism of action for MIC2634 have not been disclosed by the company.

Beyond the preview

Go deeper on MIC2634.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MIC2634.

Explore the full profile